GSK Malaria Vaccine Disappoints In Phase III Africa Trials, But Continues
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline's RTS,S/AS01 malaria vaccine demonstrated only modest results in a Phase III trial on African children, a setback for what would be the first preventative for the disease more than 20 years in the making.